ACT Brief: Sponsor Accountability in Outsourcing, Biomarker Strategy in Precision Oncology, and Novel Sciatica Therapy

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part one of a new interview, Elizabeth Walsh, founder of Walsh Clinical Advisory and co-author of The Clinical Execution Blueprint, explained why the belief that outsourcing execution transfers accountability represents the most consequential and least examined gap in how sponsor organizations are structured. This assumption shapes how sponsors delegate responsibility with direct consequences for program execution and risk ownership.
• In a contributed article on precision oncology, the author examined why Phase III trial failures in targeted therapies often reflect incomplete understanding of tumor biology rather than target selection alone. Robust biomarker strategy requires pressure-testing assumptions early, understanding patient heterogeneity across subgroups, and moving beyond single-marker approaches toward multi-dimensional patient selection that accounts for tumor evolution and resistance mechanisms.
• FDA cleared an investigational new drug application for Consano Bio's C-1101, a novel platelet-derived biologic delivered via epidural injection to treat chronic sciatica by modulating inflammation and stimulating nerve repair. The Phase I trial will expand to US sites following initial dosing in Australia, potentially establishing the first disease-modifying, non-opioid pharmaceutical treatment for a condition currently lacking approved drug therapy.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.